Cancer Vaccine Institute News

On the Cancer Research Frontier is a series spotlighting the scientists, doctors, nurses, patients, and philanthropists at the Cancer Vaccine Institute. Join us in meeting the brilliant minds behind our cancer vaccines and immunotherapies as they share their professional journeys and personal stories. On the dance floor, Meera Suresh moves her body rhythmically to the lively percussion, her facial expressions sharp and focused. Her arms move in angular patterns to the beat wh

The Cancer Vaccine Institute (CVI) is proud to share a review article published today in the Journal of the American Medical Association (JAMA) that highlights how far the field of cancer vaccines has come and why it’s at a true tipping point. Decades of research have brought us to a moment where the essential pieces are finally in place: hundreds of tumor antigens identified, a clear understanding of the immune responses needed for cancer eradication, safe and effective vacc

The biggest challenge in ovarian cancer isn’t getting to remission - it’s staying there. Recurrence rates are high, especially for advanced disease. Nineteen-year survivor and CVI vaccine recipient Jamie Crase captures that stark reality: “Stage 4 ovarian cancer has a 90-95% chance of recurrence after the initial treatment. The odds were not in my favor.” At the Cancer Vaccine Institute, we are changing the odds in the favor of Jamie and all patients diagnosed with this deadl

For those impacted by ovarian cancer, September is more than just another month. It’s Ovarian Cancer Awareness Month, a time to raise awareness for a disease that remains underfunded and underrecognized, and a moment for patients and families to be truly seen and heard as we push for the breakthroughs they’ve waited far too long for. Ovarian cancer is especially challenging because there are no reliable tests to catch it early. Most people are diagnosed after the disease is a

The first half of 2026 has been an exciting one at the Cancer Vaccine Institute (CVI), and we are proud to share the progress we’ve made in our Midyear Review. We have six clinical trials actively recruiting, with four additional studies opening soon. Our faculty and research teams have been recognized through competitive awards, invited presentations, and impactful scientific publications. These achievements highlight the significance of our work and elevate the visibility o